Disc Medicine licenses anti-TMPRSS6 antibodies from Mabwell; $10M upfront, up to $412.5M milestones

Disc Medicine, Inc.

Exclusive license to MWTX-003 and other anti-TMPRSS6 mAbs for US, Europe, and territories outside Greater China and SE Asia.
Upfront cash payment of $10M; total potential milestones up to $412.5M; tiered mid-to-high single-digit royalties on net sales.
MWTX-003 is phase 1-ready with FDA IND accepted; Disc plans to start phase 1 in healthy volunteers in H2 2023.
Antibodies target TMPRSS6 to modulate iron homeostasis, with potential in beta-thalassemia and polycythemia vera.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Disc Medicine, Inc. entered into Exclusive License Agreement with Mabwell Therapeutics, Inc. valued at $10 million dollars (effective 2023-01-19).

Action: entry
Agreement: license
Counterparty: Mabwell Therapeutics, Inc.
Value: $10 million dollars
Effective: 2023-01-19

Exact text from the filing

On January 19, 2023, Disc Medicine, Inc. (“Disc”) entered into an exclusive license agreement with Mabwell Therapeutics, Inc. (“Mabwell”) (a wholly-owned subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd), pursuant to which Mabwell granted Disc an exclusive and sublicensable license under certain patent rights, know-how, and materials to develop and commercialize antibody products containing Mabwell’s MWTX-001, MWTX-002, and MWTX-003 antibodies, along with limited variants thereof, in all fields of use, in all territories other than Greater China (Mainland China, Hong Kong, Macau and Taiwan) and Southeast Asia (Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand and Vietnam).

View on SEC.gov

Browse all material agreements →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-012530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.